Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR. Soularue É, et al. Among authors: bachet jb. Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3. Bull Cancer. 2015. PMID: 25744576
Cetuximab efficacy in patients treated routinely in university hospitals.
Bachet JB, Afchain P, Fermanian C, Bouchahda M, Mitry E, Landi B, André T, Lièvre A, Louvet C, Aegerter P, Levi F, Rougier P. Bachet JB, et al. Gastroenterol Clin Biol. 2007 Nov;31(11):941-9. doi: 10.1016/s0399-8320(07)78302-1. Gastroenterol Clin Biol. 2007. PMID: 18166882 Free article.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. Lièvre A, et al. Among authors: bachet jb. J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906. J Clin Oncol. 2008. PMID: 18202412
Stage II and stage III colon cancer: treatment advances and future directions.
Rousseau B, Chibaudel B, Bachet JB, Larsen AK, Tournigand C, Louvet C, André T, de Gramont A; GERCOR (French Oncology Research Group). Rousseau B, et al. Among authors: bachet jb. Cancer J. 2010 May-Jun;16(3):202-9. doi: 10.1097/PPO.0b013e3181ddc5bf. Cancer J. 2010. PMID: 20526097 Review.
Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.
Trouilloud I, Dubreuil O, Boussaha T, Lepère C, Landi B, Zaanan A, Bachet JB, Taieb J. Trouilloud I, et al. Among authors: bachet jb. Clin Res Hepatol Gastroenterol. 2011 May;35(5):364-74. doi: 10.1016/j.clinre.2011.02.002. Epub 2011 Mar 23. Clin Res Hepatol Gastroenterol. 2011. PMID: 21435966 Review.
Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.
Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T. Bachet JB, et al. Oncologist. 2012;17(4):555-68. doi: 10.1634/theoncologist.2011-0365. Epub 2012 Mar 16. Oncologist. 2012. PMID: 22426526 Free PMC article. Review.
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Maréchal R, et al. Among authors: bachet jb. Gastroenterology. 2012 Sep;143(3):664-674.e6. doi: 10.1053/j.gastro.2012.06.006. Epub 2012 Jun 13. Gastroenterology. 2012. PMID: 22705007
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A. Tournigand C, et al. Among authors: bachet jb. J Clin Oncol. 2012 Sep 20;30(27):3353-60. doi: 10.1200/JCO.2012.42.5645. Epub 2012 Aug 20. J Clin Oncol. 2012. PMID: 22915656
204 results